Generic eye-drugmaker Akorn has entered into a deal to buy Hi-Tech Pharmacal (Hi-Tech) for US$640 million in cash to expand into oral liquids and ointments, including cold and cough treatments.
Akorn to buy Hi-Tech Pharmacal for US$640 million
Home/Pharma News
|
Posted 13/09/2013
0
Post your comment

Hi-Tech is a specialty pharmaceutical business based in the US that develops, manufactures and promotes generic, brand-name and over-the-counter (OTC) drug products.
Under the terms of the agreement, Akorn will pay US$43.50 per share for Hi-Tech, which is 24% more than the closing share price of the company on 26 August 2013. The Hi-Tech deal is the third Akorn has made in recent years. US-based Akorn also acquired Advanced Vision Research in 2011 and Kilitch Drugs in 2012.
The acquisition of Hi-Tech strengthens Akorn’s current position as the third-largest company in the US market for generic ophthalmic drugs. The deal will also add brand-name OTC cough and cold, nasal and topical drug products to Akorn’s existing portfolio of eye care products. The combined company is expected to have annual revenues of more than US$500 million. Hi-Tech’s product pipeline is also expected to further enhance growth opportunities for the combined company.
The addition of Hi-Tech’s ‘difficult to manufacture liquid and semi-solid dosage forms’ will expand Akorn’s products beyond ophthalmics to other niche dosage forms, such as oral liquids, topical creams and ointments, nasal sprays and otics.
Akorn expects the deal to lead to annual savings of around US$15–20 million within 12 months of closing.
Related article
Generics of antibiotic Levaquin approved by FDA
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.
Source: Akorn
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment